May 01, 2020 Go or no go? Oncology dominates upcoming decisions Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
July 05, 2019 Cannabis, M&A and data spur strong gains among small and midcaps The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations decimating some shares.
